Calistoga Pharmaceuticals Email Format
Biotechnology ResearchWashington, United States2-10 Employees
calismiyorum is a small biotechnology company based in Seattle, Washington, focused on creating oral medicines that block selected isoforms of the PI3K signaling pathway. The PI3K axis regulates cell survival and immune activation, and the company's candidates aim to address these targets with a focus on clinical outcomes and manageable side effects. The organization concentrates its activities on cancer and inflammatory disease indications. Lead product CAL-101 is an oral compound that targets the delta isoform of PI3K and has shown activity in patients with B-cell malignancies, currently studied across several clinical trials. The development pipeline also includes additional selective PI3K inhibitors at early preclinical stages or poised to begin initial clinical testing for cancer or inflammatory diseases.